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Abstract
AIM: This study was aimed to determine the antifibrotic activity of Phaleria macrocarpa (PM) extract in liver fibrosis 
(LF) and its possible mechanism in the rat model.
METHODS: Sprague Dawley male rats were injected with 2 mL/kg BW of carbon tetrachloride intraperitoneally 
twice a week for 2 weeks, followed by 1 mL/kg BW for 6 weeks. Afterward, the treatments began from the 3rd week: 
Silymarin 100 mg/kg BW/day, standardized PM extract (Proliverenol) 75 or 150 mg/kg BW/day orally. Rats were 
sacrificed in the 8th week. Blood and liver were collected to analyze liver function, liver damage and fibrosis marker, 
oxidative stress markers, pro-fibrogenic cytokine, and antifibrotic marker.
RESULTS: Our study showed that the treatment of silymarin and PM resulted in the normalized activity of liver 
function, followed by the amelioration of oxidative stress, demonstrated by the decreased malondialdehyde levels 
and an increased ratio of glutathione and glutathione disulfide. All markers examined showed that PM extract has 
antioxidant activity due to decreased hepatic stellate cell activation. We also found a decrease in tumor growth 
factors-β1 and protein expressions of matrix metalloproteinases-13 in all treatment groups compared to the carbon 
tetrachloride group. There were tendencies of the decreased fibrotic area following improvements of biochemical 
parameters.
CONCLUSION: PM extracts ameliorate carbon tetrachloride-induced LF. The proposed mechanism is by overcoming 
oxidative stress and regulating pro-fibrogenic cytokine and antifibrotic markers.
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Introduction
Liver fibrosis (LF) is a long-lasting injury and 
inflammation in the liver. Scarring of the LF may lead 
to life-threatening complications such as cirrhosis 
and hepatocellular carcinoma (HCC) [1], [2]. LF is 
associated with a 45% mortality rate in Europe and 
the most common cause of non-neoplastic death 
in the United States [2], [3], [4]. Up to date, there 
are no antifibrotic agents available in the market. 
The approach used to treat LF is by managing the 
underlying disease [1], [3], [5].
Phaleria macrocarpa (PM) (Scheff.) Boerl., 
namely, Mahkota Dewa in Indonesia, is a member of 
the family Thymelaeaceae. Pits, stems, leafage, and 
fruits of PM were widely used as natural sources of 
medical plants in Indonesia [6]. PM, mainly grains, 
has been used empirically to treat cancer, allergy, 
and diabetes mellitus [6], [7]. Many studies have 
elucidated the chemical compounds of PM, which 
consists of mahkoside A, mangiferin, kaempferol-3-
O-β-glucoside, dodecanoic acid, palmitic acid, ethyl 
stearate, fevicordin-A, and sucrose [6], [7], [8]. PM also 
has been studied for its antioxidant, anti-inflammatory, 
cytotoxicity, antihistamine, and hepatoprotective 
effects [7], [8], [9].
The hepatoprotective activity of this PM 
extract was reported by Berlian et al. [10] using in vitro 
ethanol-induced LF model. PM extracts suppressed 
the expressions of NF-κB, TNF-α, and caspase-8 [10]. 
Hendra et al. [6] also reported that PM fruit extract 
has antioxidant and anti-inflammation using an in vitro 
model. Antioxidant was proven by ferric thiocyanate 
(FTC), thiobarbituric acid (TBA), and 2,2-diphenyl-1-
picrylhydrazyl (DPPH) assay. The anti-inflammatory 
effect was determined by nitric oxide (NO) inhibitory 
effect [6]. In accordance with their results, Sundari 
et al. [9] confirmed the protective effect using the in vivo 
model. PM extracts prevent CCl4-induced fibrosis 
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through its antioxidant and anti-inflammatory activities 
[9]. Other studies also reported that the upregulation of 
the NF-kB transduction pathway and lipid peroxidation 
is critical in LF [1], [2], [3], [11]. Considering all the 
above facts, we presume that PM extracts might have 
the antifibrotic activity to attenuate LF. Hence, this 
study was aimed to determine the antifibrotic activity of 
PM extracts and investigate its mechanism in carbon 
tetrachloride-induced LF in male rats.
Materials and Methods
 PM aqueous extract (Proliverenol) and 
silymarin
The dried powder PM extract (Proliverenol) was 
prepared by Dexa Laboratories of Biomolecular Sciences 
(Batch No. RP130116), as described by Kim et al. [8] and 
Berlian et al. [10]. Proliverenol was a bioactive fraction 
extracted from P. macrocarpa fruit using subcritical water 
extraction, as described by Kim et al. [8]; Berlian et al. [10]; 
and Sundari et al. [9]. Slivers of PM fruits were macerated 
using water-based solvent and carried out extraction under 
temperatures of 373K, pressures 4.0 MPa for 5 h. The yield 
extract was then filtered, evaporated, dried, and collected 
in a tube. High purity silymarin (81.32%) was purchased 
from Plamed Science Technology Company (Xian, China).
Experimental design 
Sprague Dawley male rats (200–350 g) were 
maintained on a 12-h light/dark cycle and allowed free 
access to food and water. The protocol was approved 
by the Animal Care Ethics Committee from the Faculty 
of Medicine, Universitas Indonesia. The flow of the 
experiments done in the study is depicted in Figure 1. The 
total sample in this experiment is 25 rats divided into five 
groups. The number of rats per group was decided based 
on sample calculation by Charan et al. [12]. Five rats were 
allocated to a healthy control group. The other 20 rats were 
treated with an intraperitoneal injection of 2 mL/kg CCl4 
(carbon tetrachloride, Merck, Germany) in olive oil (1:1) 
twice weekly for first 2 weeks and followed by 1 mL/kg 
weight for 6 weeks [13], [14], [15]. The 20 rats of the liver-
fibrosis induced were randomly divided into four groups of 
five rats: CCl4 only (untreated liver-fibrosis model); CCl4 
+ silymarin 100 mg/kg/day (Sil), CCl4 plus PM extract 75 
(T75), and CCl4 plus 150 mg/kg/day (T150) orally on the 
3rd week. After 8 weeks, all animals were sacrificed by 
decapitation (3 days after the last injection of CCl4) [14]. 
Biochemistry analysis
The whole blood was collected in a heparin 
tube and centrifuged 3000 rpm for 10 min [16]. Obtained 
plasma was analyzed for alanine transaminase 
(ALT), aspartate transaminase (AST), and alkaline 
phosphatase (ALP). Those were quantified using 
kit DiaSys (Int. Holzheim, Germany). Liver tissue 
was homogenized and used for oxidative stress 
and concentrations of TGF-β1. Oxidative stress was 
determined by the MDA level and GSH/GSSG ratio. 
MDA level was analyzed by thiobarbituric acid (TBA) 
assay, while GSH/GSSG ratio was measured according 
to the manufacturer’s protocol (Cell Biolabs Inc, San 
Diego, USA). The concentration of TGF-β1 in liver 
tissue was quantified using ELISA kit TGF-β1 according 
to the manufacturer’s protocol (Novateinbio, MA, USA).
Figure 1: The flow of experiments throughout the study. CCl4: Carbon 
tetrachloride, Sil: Silymarin 100 mg/kg/day, T75: PM extract 
75 mg/kg/day; T150: PM extract 150 mg/kg/day. n: number of rats
Histopathology and Immunohistochemistry 
analysis
Section of the area around central vein from all 
rat livers was sliced, fixed in 10% buffered formalin, and 
made in a paraffin-embedded block. Histopathology 
analysis was done to determine the accumulation of 
connective tissue by Masson’s trichrome staining [17]. 
While MMP-13 was detected by immunohistochemistry, 
as described in the manufacturer’s procedure using 
primary antibody from Santa-Cruz (sc-101564, USA) 
and NovolinkTM Polymer Detection System from Leica 
Biosystems (RE7290-K, USA). We analyzed the degree 
of fibrosis in histopathology and assessed quantitatively 
using the J-Image software image processor. 
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Statistical analysis
All the graphs and statistical tests were done 
using GraphPad Prism 8 (USA) software. The results 
were expressed as mean ± standard deviation (SD). The 
differences among groups were analyzed by one-way 
analysis of variance (ANOVA) and followed by post hoc 
Tukey analysis when data were normally distributed and 
had homogeneous variance. Kruskal–Wallis followed 
by Mann–Whitney tests were used when the data did 
not meet the requirement for parametric analysis. A 
p < 0.05 is considered statistically significant.
Results
After 8 weeks of CCl4 administration, the CCl4 
group showed a significant increase in ALT, AST, and 
ALP activity in plasma as hepatic injury markers. Sil, 
T75, and T150 groups showed ameliorated all of the 
markers significantly (Figure 2).
Figure 2: Silymarin and Phaleria macrocarpa extracts enhance the 
activity of (a) ALT, (b) AST, and (c) ALP after 8 weeks of CCl4-induced 
LF. Data are expressed as mean ± SD. CCl4: Carbon tetrachloride, 
Sil: Silymarin 100 mg/kg/day, T75: PM extract 75 mg/kg/day; T150: 
PM extract 150 mg/kg/day. #p < 0.05 versus control group; *p < 0.05 
versus CCl4 group. There was a significant decrease in the activity 
of ALT, AST, and ALP in silymarin and PM extracts as compared to 
the CCl4 group. Silymarin decreased the activity of ALT and AST, 
approaching the values of those in the control group
a b c
Our findings in the liver function markers are 
supported with histopathology results, as shown in Figure 3.
Figure 3: Silymarin and Phaleria macrocarpa extract attenuated the 
effect  of  8-week  of CCl4-induced  liver  fibrosis  by  decreasing  fibrosis 
area.  (a)  Histopathology  overview,  which  represents  each  treatment 
group using Masson’s Trichrome Staining  (magnification: ×400). The 
blue color represents an accumulation of connective tissue surrounding 
area branches of the hepatic artery, portal vein, and bile duct. (b) 
Quantification results of fibrosis area using image processor. Data are 
expressed as mean ± SD. CCl4: Carbon tetrachloride, Sil: Silymarin 
100mg /kg/day, T75: PM extract 75 mg/kg/day; T150: PM extract 150 
mg/kg/day. #p < 0.05 versus control group; *p < 0.05 versus CCl4 group
ba
The percentage of fibrosis area in the CCl4 
treated group resulted in fibrosis was significantly 
increased as compared to normal. Silymarin and 
PM extract reduced the percentage of fibrotic areas, 
although the decline had not approached the control 
group. 
LF induced by CCl4 was clearly shown in the 
CCl4 group, with a significant increase in the area of 
fibrosis and hepatic oxidative stress marker (MDA) as 
compared to the control group (Figure 4a). The GSH/
GSSG ratio was shown to decline to compensate 
for oxidative stress that occurs on LF pathogenesis. 
Both silymarin and PM extracts in two different doses 
ameliorate fibrosis area, reduced MDA levels, and 
increased the GSH/GSSG ratio significantly compared 
to the CCl4 group (Figure 4b).
Figure 4: Silymarin and Phaleria macrocarpa extracts improve 
oxidative stress markers in CCl4-induced  liver  fibrosis  as 
shown  by  (a)  malondialdehyde  levels,  (b)  ratio  of  GSH/GSSG 
Data are expressed as mean ± SD. CCl4: Carbon tetrachloride, Sil: 
Silymarin 100mg /kg/day, T75: PM extract 75 mg/kg/day; T150: PM 
extract 150 mg/kg/day. #p < 0.05 versus control group; *p < 0.05 
versus CCl4 group
ba
Data are expressed as mean ± SD. CCl4: Carbon 
tetrachloride, Sil: Silymarin 100mg /kg/day, T75: PM 
extract 75 mg/kg/day; T150: PM extract 150 mg/kg/day. 
#p < 0.05 versus control group; *p < 0.05 versus CCl4 
group.
Chronic CCl4 administration for 8 weeks 
increased the TGF-β1 levels and in line to a percentage of 
the positive expressions of MMP-13. Sil and PM extracts 
ameliorate levels of TGF-β1 and reduced the percentage 
of the positive expressions of MMP-13 (Figure 5).
Figure 5: Phaleria macrocarpa extracts elevated (a) levels of TGF-β1 
and (b) the percentage of area with positive expressions of MMP-13 
(immunohistochemistry). Data are expressed as mean ± SD. CCl4: 
Carbon tetrachloride, Sil: Silymarin 100 mg/kg/day, T75: PM extracts 
75 mg/kg/day; T150: PM extracts 150 mg/kg/day. #p < 0.05 versus 
control group; *p < 0.05 versus CCl4 group
ba
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Discussion
The present study aimed to investigate PM 
extracts’ efficacy and mechanism for the treatment of 
LF. CCl4 was used to induce LF that involved oxidative 
stress and followed persistent inflammation as same 
as happened in chronic liver disease [12], [13], [14]. 
Chronic administration of CCl4 for 8 weeks caused 
liver damage characterized by an increase of ALT, 
AST, and ALP activity in plasma. As described by 
Hayashmi et al. [12], Truong et al. [16], and Li L 
et al., [18], the mechanism of CCl4 is trichloromethyl 
and trichloromethyl peroxide radicals is attacked the 
endoplasmic reticulum membrane and leading to lipid 
peroxidation [12], [16], [18]. CCl4 chronic treatments 
lead to impaired membrane permeability so that the 
enzymes in the cytosol and mitochondria of hepatocytes 
will come out into plasma. Consequently, there are 
increased activities of those in plasma [16].
ALT and AST are enzymes located in the cytosol 
of hepatocytes that are involved in the gluconeogenesis 
process. Hepatocyte injury can lead to increased activity 
of them up to more than 2 times normal [18]. [19], [20]. 
We showed a significant increase in ALT and AST 
enzyme activity in the CCl4 group, more than 2 times 
from normal value. These results are in line with other 
studies by Constandinou et al. [13], Tzeng et al. [21], 
Bona et al. [22], and Deng et al. [23]. In contrast to our 
results, Tsai et al. [24] reported that the treatment of 
CCl4 only caused an increase of ALT and AST less than 
twice compared to the control group, though they found 
clear signs of LF in histopathology samples. 
ALP is an enzyme that catalyzes the hydrolysis 
process of organic phosphate to inorganic phosphate. 
Increased activity of ALP for 3–10 times from normal 
value is the result of cholestasis and obstruction of intra 
and extra biliary [16]. CCl4 in this study has caused an 
increase of ALP activity more than 3 times the standard 
value. It indicated that chronic administration of CCl4 
causes bile duct disorders. These results are consistent 
with the findings by other researchers similar to Bona 
et al. [22], Tuncer et al. [25], and Amin et al. [26] that 
used CCl4 to induce fibrosis. 
The increase in the three markers showed signs 
of chronic injury of the liver caused by CCl4, which is a 
good fibrosis model. This fibrosis model was used to study 
PM extract’s antifibrotic activity (75 and 150 mg/kg/day). 
Doses used in this study were determined from the 
previous research [9], [10]. Silymarin (Sil) has been 
reported to stop the progression of LF effectively in vitro 
and in vivo by improving histopathology and decreased 
biochemical parameters [24], [27]. It has been used for 
patients who have NAFLD and alcoholic liver disease 
(ALD). It improved biochemical parameters (AST, 
ALT, and GGT), ameliorate inflammation through the 
reduction in TNF-α serum levels, and decrease hepatic 
steatosis degree, which followed by improvement in 
histopathology [28], [29]. Silymarin is leading to inhibit 
HSCs activation and protect hepatocytes from apoptosis 
when oxidative stress occurs in LF [3], [27]. Silymarin 
was known to scavenge free radicals, thereby inhibiting 
lipid peroxidation. It also has an anti-inflammatory effect 
by inhibiting intrahepatic activation of the transcription 
factor NF-kB. Thus, decreasing the release of TNF-α, 
IFN-γ, IL-2, and inducible NO synthase (iNOS) that plays 
a role in the process of chronic inflammation as well as 
LF [29], [30]. In the previous study, PM extract inhibits the 
NF-kB pathway and decreases lipid peroxidation [9], [10]. 
Therefore, silymarin was chosen as a comparator. In 
line with our findings, a study by Mostafa et al. reported 
that the administration of silymarin 100 mg/kg/day 
decreased ALP activity significantly compared with the 
fibrosis group [31]. Studies by Tsai et al. and Amin et al. 
had also shown a decrease in ALP enzyme activity after 
administration of silymarin 200 mg/kg [24], [26].
Improvement in liver function tests by all 
treatment groups was in line with the findings in the 
percentage of fibrosis area. In agreement with our 
study, Tsai et al. [24], Amin et al. [22], and Lee et al. [32] 
reported that the administration of silymarin caused 
liver improvement in histopathology examination.
CCl4 leads to oxidative stress, causes damage to 
hepatocytes, and further induces fibrogenesis in chronic 
exposure [13], [16], [18]. Imbalance redox status occurred 
due to the increased free radicals from CCl4 metabolites 
and the lack of endogenous antioxidant capacity. Those 
were described by elevation MDA levels (lipid peroxidation) 
and declining GSH/GSSG ratio (endogenous antioxidant 
capacity) [33], [34], [35]. MDA levels were higher in 
CCl4 than the control group, which showed elevation of 
lipid peroxidation. All therapy groups improved the level 
of MDA. CCl4 produced those due to their ability to 
scavenge free radicals, thus inhibiting lipid peroxidation in 
hepatocytes [10], [27], [30]. GSH/GSSG ratio declined in 
the CCl4 group compared to the control group. Silymarin 
and PM extract improved GSH/GSSG ratio, which is 
higher than the CCl4 group and approached the control 
group. Studies done by Tzeng et al. [21] and Kiruthiga 
et al. [36] showed that silymarin increased endogenous 
antioxidant activity by improving the glutathione peroxidase 
activity (GPx), manganese superoxide dismutase 
(Mn-SOD), and cooper/zinc-superoxide dismutase 
(Cu/Zn-SOD) [21], [36]. The increase of endogenous 
antioxidant activity illustrated elevation GSH availability to 
form conjugates with CCl3OO˙ and COCl2 (free radical, 
which is CCl4 metabolites). The antioxidant activity of the 
PM extract might mediate the anti-fibrosis effect. 
The possible mechanism of antifibrotic activity 
is by regulating TGF-β1 and MMP-13. Decreased TGF-
β1 levels reduce the activation of hepatic stellate cells, 
which further inhibits fibrogenesis. While as a marker 
for antifibrotic activity, we measure MMP-13, which acts 
by degrading ECM in LF [13], [37], [38]. We found that 
silymarin and PM extracts reduced the TGF-β1 levels. 
However, the improvement has not reached the normal 
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level, which indicates that silymarin and PM treatment 
have not been able to normalize TGF-β1 levels. In line 
with our findings, Li et al. [39] showed the decline of 
TGF-β1 in a higher dose (200 mg/kg/day), and longer 
duration of silymarin still could not normalize profibrotic 
cytokines. Reversal of LF normalization has also not 
been successful with other drugs such as pioglitazone 
and phloridzin [14], [23].
MMP-13 is a specific protease capable of 
degrading collagen type I in rodents [10], [14], [34]. 
MMP-13 in rodents has functions similar to MMP-1 in 
humans and is required to maintain the homeostasis of 
ECM on rodents [40], [41].
In LF, Kupffer cells, hepatic stellate cells, 
and activated myofibroblast will produce MMP-13 
for degrading collagen I, resulting in decreased ECM 
composition [13], [40]. We showed an elevation 
percentage of the positive expressions of MMP-13 
in the CCl4 group, even not approaching the healthy 
group. This finding was in agreements with studies 
done by Iridale et al. [40] and Chen et al. [42] Iridale 
et al. reported that the expression of MMP-13 increases 
in experimental fibrosis model, which is induced by 
CCl4 intraperitoneally in the same regimen in this study 
for 4 weeks [41]. The decline was not as apparent as 
the improvement of histopathology examination [41]. 
While Chen et al. reported that there were increased 
expressions of MMP-2, MMP-8, MMP-9, MMP-13, 
TIMP-1, and TIMP-2 in the fibrosis model group due to 
administration of TAA [42]. 
Iridale et al. [40] and Leclercq et al. [14] 
found that CCl4 induction similar dose in this study 
can increase MMP-13, which differs significantly from 
the control group. Ginanndrea et al. [43] reported that 
in the early phase of fibrogenesis, and myofibroblast 
activation occurs, followed by the release of pro-
inflammatory cytokines (such as TNF-α and IL-1) and 
pro-fibrogenic cytokines (TGF-β1). TNF-α induces 
activation and expression of MMP-13. Both cytokines 
are released by extra-hepatic macrophages, Kupffer 
cells, and HSCs when activated [40], [43]. Uchinami 
reported that the elevation TNF-α during peak LF is 
accompanied by increased expression of MMP-13 [44]. 
In our experiments, the MMP-13 in the CCl4 group 
was increased. As described by Iridale et al. [40] and 
Uchinami et al. [44], it possibly occurred due to the 
continuous activation of hepatic stellate cells, which 
resulted in myofibroblast activation.
There was a tendency to decline in the positive 
expressions of MMP-13 in all treatment groups, 
silymarin, and PM extracts. The phenomenon might 
occur due to inhibition of hepatic stellate cells and 
myofibroblast activation by silymarin and PM extract. 
Therefore, activation of MMP-13-producing cells 
has decreased, although those are higher than the 
control group. It is in accordance with a study, which 
is conducted by Chen et al. [42]. They reported that 
silymarin could reduce the expression of MMP-13.
In contrast, Leclercq et al. [14] reported that 
pioglitazone for 3 weeks and 7 weeks led to MMP-13 
elevation, which was significantly different compared 
to the CCl4 group and baseline [14]. Another study 
done by Kawaguchi et al. found that pioglitazone 
could prevent the activation of HSCs by reducing the 
mRNA expression of collagen type I, MMP-2, TIMP-1, 
and TIMP-2 and increased the expression of MMP-13 
mRNA [41]. However, an in vivo study by Kawaguchi 
et al. showed declining mRNA expression of TIMP-1 
and TIMP-2 with no increase in MMP-13 [45].
MMP-13 alone could not adequately 
describe the process of ECM degradation. However, 
the process of ECM degradation can be seen from 
the percentage of fibrosis area. It tends to decrease, 
although not significant, compared to the CCl4 
group. It happened because there are two working 
mechanisms of MMP-13. First, MMP-13 will directly 
degrade collagen types I and III then resulting in 
decreased ECM accumulation. Its process is leading 
to LF resolution [40], [41], [42], [43], [46]. Second, 
MMP-13 can activate pro-HGF (hepatocytes pro-
growth factors) to HGF. HGFs bind to the c-Met 
receptor and subsequently induce the expression 
of MMP-2 and MMP-9 [47]. In accordance, Iridale 
et al. showed that increasing MMP-13, followed by 
decreasing of TIMP-1 and TIMP-2 in fibrosis [40]. 
Then, the expressions of TIMP-1 and TIMP-2 reduce 
when LF occurs without MMP-13 reduction [40].
Furthermore, the presence of pro-
inflammatory (TNF-α and IL-1) and pro-fibrogenic 
(TGF-β1) cytokines can affect the expression of MMPs 
and TIMP [40], [44]. Elevation of pro-inflammatory 
cytokines, lead to the induced expression of MMP-13. 
Nevertheless, pro-fibrogenic cytokine PM extract at T75 
and T150 groups decreases the activity of ALT and AST 
significantly compared to the CCl4 group. Our findings are 
consistent with results from the previous study, in which 
proven PM extract is shown to ALT and AST activity in 
rats induced ethanol [9], [11]. ALP levels decreased in 
all treatment groups, however, not enough to reach the 
value of the control group. Mostafa et al.  [31] reported 
the administration of Sil, 100 mg/kg/day decreased ALP 
activity significantly compared with the fibrosis group 
(CCl4) to near normal values. TGF-β1 only induced 
expression of TIMPs, not MMPs [40], [47], [48]. Thereby, 
silymarin and PM extracts have improved liver 
function test markers through decreased ALT, AST, 
and ALP activity, followed by oxidative stress markers 
improvement through declined MDA levels and as the 
elevation of GSH/GSSG ratio.
PM extracts are shown to have antioxidative 
activity by the prevention of hepatocyte damage due 
to CCl4. The antioxidant activity may decrease HSCs 
activation and myofibroblast and further decrease 
the pro-fibrogenic cytokine (TGF-β1) has decreased. 
Along with that, expressions of MMP-13 declined in 
all treatment groups compared to the CCl4 group. This 
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shows PM extracts’ antifibrotic activity on LF reversal 
through the improvement of all the biochemical 
parameters, followed by the tendency to decrease 
the fibrosis percentage area. The activation of HSCs 
by PM was not determined, which was the limitation 
of our study. This activation has a pivotal role in LF. 
Therefore, it remains unclear the mechanism of PM 
extract on HSCs activation, as well as TIMPs and 
MMPs regulation. 
Conclusion
PM extract has anti-fibrosis by improving 
liver functions (AST and ALP), declining MDA levels, 
elevating GSH/GSSG ratio, decreasing TGF-β1 
concentrations, and MMP-13 expressions. However, 
these effects were not enough to normalize the fibrosis 
effect. 
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